# Diagnosis and stabilisation of familial chylomicronemia syndrome in two infants presenting with hypertriglyceridemia‐induced acute pancreatitis

**Authors:** Oliver Heath, Brooke Allender, Joel Smith, Elena Savva, Lucy Spencer, Elizabeth G. Bannister, Natasha J. Brown, Maureen S. Evans, Sharmila Kiss, Thomas H. Rozen, Joy Yaplito‐Lee

PMC · DOI: 10.1002/jmd2.12434 · JIMD Reports · 2024-06-02

## TL;DR

This paper describes the diagnosis and treatment of two infants with a rare genetic disorder causing severe fat metabolism issues and pancreatitis.

## Contribution

The study provides insights into managing familial chylomicronemia syndrome in infants with acute pancreatitis.

## Key findings

- Two infants with LPL gene mutations presented with severe hypertriglyceridemia and acute pancreatitis.
- Acute stabilization involved insulin, heparin, and a specialized diet low in long-chain triglycerides.
- Adequate caloric intake was crucial for reducing triglyceride levels during acute management.

## Abstract

Familial chylomicronemia syndrome (FCS) is a rare disorder of triglyceride (TG) metabolism caused by loss of function variants in one of five known canonical genes involved in chylomicron lipolysis and clearance—LPL, APOC2, APOA5, LMF1, and GPIHBP1. Pathogenic variants in LPL, which encodes the hydrolytic enzyme lipoprotein lipase, account for over 80%–90% of cases. FCS may present in infancy with hypertriglyceridemia‐induced acute pancreatitis and is challenging to manage both acutely and in the long‐term. Here, we report our experience managing two unrelated infants consecutively diagnosed with hypertriglyceridemia‐induced acute pancreatitis caused by LPL deficiency. Both had elevated TGs at presentation (205 and 30 mmol/L, respectively) and molecular genetic testing confirmed each infant carried a different homozygous pathogenic variant in the LPL gene, specifically, c.987C>A (p.Tyr329Ter) and c.632C>A (p.Thr211Lys). The more severely affected infant had cutaneous xanthomata, lipemia retinalis and lipemic plasma at presentation, and required management in an intensive care setting. Acute stabilisation was achieved using insulin and heparin infusions together with the iterative implementation of a fat‐restricted diet, low in long chain triglycerides (LCT) and supplemented with medium chain triglycerides (MCT). In both cases, provision of adequate caloric intake (~110–120 kcal/kg/day) was also found to be important for a sustained TG reduction during the acute phase of management. In summary, a high index of suspicion is required to diagnose FCS in infants with hypertriglyceridemia‐induced acute pancreatitis, management of which can be challenging, highlighting the need for more evidence‐based recommendations.

## Linked entities

- **Genes:** LPL (lipoprotein lipase) [NCBI Gene 4023], APOC2 (apolipoprotein C2) [NCBI Gene 344], APOA5 (apolipoprotein A5) [NCBI Gene 116519], LMF1 (lipase maturation factor 1) [NCBI Gene 64788], GPIHBP1 (glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1) [NCBI Gene 338328]
- **Diseases:** familial chylomicronemia syndrome (MONDO:0009387)

## Full-text entities

- **Genes:** LMF1 (lipase maturation factor 1) [NCBI Gene 64788] {aka C16orf26, HMFN1876, JFP11, TMEM112, TMEM112A}, GPIHBP1 (glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1) [NCBI Gene 338328] {aka GPI-HBP1, HYPL1D}, LPL (lipoprotein lipase) [NCBI Gene 4023] {aka HDLCQ11, LIPD}, APOA5 (apolipoprotein A5) [NCBI Gene 116519] {aka APOAV, RAP3}, APOC2 (apolipoprotein C2) [NCBI Gene 344] {aka APO-CII, APOC-II}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}
- **Diseases:** lipemic plasma (MESH:D054219), cutaneous xanthomata (MESH:D018366), lipemia retinalis (MESH:D006949), hypertriglyceridemia (MESH:D015228), acute pancreatitis (MESH:D010195), FCS (MESH:D008072)
- **Chemicals:** TGs (MESH:C026285), heparin (MESH:D006493), MCT (MESH:C000709826), LCT (-), TG (MESH:D014280)
- **Mutations:** c.987C>A, p.Thr211Lys

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11224501/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC11224501/full.md

## References

38 references — full list in the complete paper: https://tomesphere.com/paper/PMC11224501/full.md

---
Source: https://tomesphere.com/paper/PMC11224501